Related Experiment Video
Updated: May 9, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
[Antithrombotic medications and childhood stroke]
Stéphane Chabrier1, Manoëlle Kossorotoff, Stéphane Darteyre
1CHU de Saint-Étienne, hôpital Bellevue, service de médecine physique et de réadaptation pédiatrique et Centre national de référence de l'AVC de l'enfant, 42055 Saint-Étienne, France; Université Saint-Étienne, EA3065 Groupe de recherche sur la thrombose, 42023 Saint-Étienne, France.
Insights
Pediatric stroke guidelines are updated using limited evidence, recommending anticoagulation for cerebral sinovenous thrombosis and aspirin for arterial ischemic stroke recurrence prevention in children.
Area of Science:
- Neurology
- Pediatrics
- Vascular Medicine
Context:
- Childhood stroke affects 500-1000 children annually in France, often resulting in persistent neurological deficits.
- Current pediatric stroke guidelines rely on observational data, adult recommendations, and expert consensus due to a lack of high-level evidence.
Purpose:
- To review current evidence and expert opinion on managing pediatric stroke.
- To highlight treatment considerations for specific pediatric stroke types, including cerebral sinovenous thrombosis and arterial ischemic stroke.
- To identify gaps in knowledge and advocate for improved research methodologies in pediatric stroke.
Summary:
- Anticoagulation is recommended for acute pediatric cerebral sinovenous thrombosis, with individualized treatment duration.
- Aspirin effectively reduces recurrence risk in pediatric arterial ischemic stroke.
- Thrombolysis and mechanical devices show potential for recanalization but lack sufficient evidence for widespread pediatric use.
- Neonatal stroke management remains unclear.
- Development of new studies focusing on easily administered antithrombotic drugs and rare disease populations is needed.
Impact:
- Informs clinical practice for pediatric stroke management.
- Highlights the need for evidence-based guidelines tailored to children.
- Guides future research directions for antithrombotic therapies in pediatric stroke.
- Emphasizes the importance of specialized trial designs for rare pediatric conditions.
Abstract:
Each year, 500 to 1000 children experience a stroke in France. Long-term follow-up demonstrates persistent neurologic deficit in most of them. Despite the lack of studies with high level of evidence, paediatric stroke guidelines are regularly updated based on observational data, analogy with recommendation for adults, and expert opinion. It is reasonable to initiate anticoagulation during the acute phase of cerebral sinovenous thrombosis in children; the duration of anticoagulation needs to be individually tailored. It is not yet possible to draw any conclusions regarding neonates. Intravenous or intra-arterial thrombolysis and mechanical devices have the potential to provide instant and safe recanalization under optimal circumstances, but no generalization about their efficacy in childhood ischemic stroke can be drawn. Aspirin is effective in reducing the risk of recurrence in children with arterial ischemic stroke. There is a need to develop new studies with easy for use of antithrombotic drugs, such as aspirin or oral direct factor Xa inhibitors. A specific approach for rare disease population, which follows guidance for the design and conduct of paediatric trials, is required.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Ischemic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
